Ownership history in Rye Brook Capital LLC · 19 quarters on record
This page tracks every 13F SEC filing in which Rye Brook Capital LLC reported a position in ISHARES NASDAQ BIOTECHNOLOGY (IBB). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q3 | REDUCED | 24,270 | -30 | -0.1% | 1.82% | $3.5M | $144.11 |
| 2025 Q2 | ADDED | 24,300 | +2,800 | +13.0% | 3.21% | $3.1M | $126.21 |
| 2025 Q1 | ADDED | 21,500 | +200 | +0.9% | 3.45% | $2.8M | $127.59 |
| 2024 Q4 | ADDED | 21,300 | +2,000 | +10.4% | 3.38% | $2.8M | $131.78 |
| 2024 Q2 | REDUCED | 19,300 | -21,100 | -52.2% | 3.48% | $2.6M | $136.56 |
| 2024 Q1 | ADDED | 40,400 | +400 | +1.0% | 3.25% | $5.5M | $136.52 |
| 2023 Q4 | REDUCED | 40,000 | -900 | -2.2% | 2.78% | $5.4M | $135.03 |
| 2023 Q3 | ADDED | 40,900 | +100 | +0.2% | 3.56% | $5.0M | $121.44 |
| 2023 Q2 | ADDED | 40,800 | +700 | +1.7% | 2.45% | $5.2M | $125.92 |
| 2023 Q1 | ADDED | 40,100 | +50 | +0.1% | 3.17% | $5.2M | $128.10 |
As of 2025 Q4 — sorted by position size